Pfizer stacks profits after selling US government 200 million more COVID vaccinations

While rarely mentioned in the mainstream media, it goes without saying that COVID-19 vaccine production has proven to be an extremely lucrative venture for the major pharmaceutical companies who make them, especially when the U.S. government comes knocking on their doors for more.

According to the Washington Examiner, that’s exactly what’s happening in the case of Pfizer and BioNTech, as they locked down the sale of a staggering 200 million additional doses of the COVID-19 vaccine to the federal government. Those particular doses have the ability to be “upgraded” to be more effective against COVID-19 variants and/or used as a third booster shot. 

As The New York Times reported earlier this year, Pfizer alone had already added “hundreds of millions” in profit to their bottom line as a result of COVID-19 vaccine sales.

One can only imagine what that number must look like at this point, especially on the heels of another massive sale to the government.

What’s going on?

According to a press release from Pfizer and BioNTech, the latest sale brings the total number of doses sold to the U.S. government to over 500 million. Another 500 million COVID-19 vaccinations will be distributed by the companies on a global scale.

The latest sale of 200 million doses of the vaccine will reportedly “be delivered from October 2021 through April 2022,” the statement noted.

Not long ago, Pfizer warned that it might be necessary to provide a third round of shots for those who’ve already received the two rounds required to be fully vaccinated, CNBC noted.

Though the government hasn’t changed its position on sticking with two shots, now that the Delta variant of the virus is spiking case counts across the country, it’s not a stretch to predict that a third round of booster shots could soon receive the government’s backing.

“Proud of the impact”

In the press release, Pfizer CEO Albert Bourla praised his employees for their hard work on formulating a COVID-19 vaccine and getting it out to the masses in a relatively short amount of time. However, some believe the rapid deployment of the vaccine contributes to increased vaccine hesitancy, given the lack of the Food and Drug Administration’s (FDA) stamp of approval.

“As a long-term partner to the U.S. government in the fight against this pandemic, we are proud of the impact of vaccination efforts across the country. Vaccines have been and will remain critical to protecting lives against this devastating disease,” Bourla said.

“These additional doses will help the U.S. government ensure broad vaccine access into next year,” the Pfizer CEO added.

A number of conservative commentators have suggested that Pfizer and other pharmaceutical companies are exploiting the pandemic to reap unprecedented profits, and given that Pfizer and others are pushing for additional booster vaccinations, it’s not unreasonable to consider that the companies might not have our best interests at heart.

Latest News